PMID- 29438634
OWN - NLM
STAT- MEDLINE
DCOM- 20191011
LR  - 20200306
IS  - 2159-9777 (Electronic)
IS  - 0279-1072 (Print)
IS  - 0279-1072 (Linking)
VI  - 50
IP  - 1
DP  - 2018 Jan-Mar
TI  - Regulating Cannabis Manufacturing: Applying Public Health Best Practices from 
      Tobacco Control.
PG  - 19-32
LID - 10.1080/02791072.2017.1422816 [doi]
AB  - State legalization and regulation of cannabis, despite continued federal 
      illegality, is a massive shift in regulatory approach. Manufactured cannabis, 
      including concentrates, extracts, edibles, tinctures, topicals and other 
      products, has received less attention than more commonly used dried flower, but 
      represents emerging regulatory challenges due to additives, potency, consumption 
      methods, and abuse and misuse potential. In November 2017, the California 
      Department of Public Health (CDPH) released initial cannabis manufacturing 
      regulations as part of a new state regulatory structure. As the largest U.S. 
      medical cannabis market (and largest legal adult use market in the world 
      beginning in 2018), California's regulatory approach will potentially influence 
      national and global policy. Comparing CDPH's initial regulations to tobacco 
      control best practices reveals that, while the regulations recognize the need to 
      protect public health, prioritizing public health over business interests 
      requires stronger approaches to labeling, packaging, and product formulations. 
      Based on tobacco best practices, we recommend that cannabis regulations 
      incorporate large and proportionately sized informational labels, a prominent 
      universal cannabis symbol, rotating and pictorial health warnings, mandatory 
      plain packaging, a comprehensive ban on characterizing flavors and addictive 
      additives, and strict limits on the potency of inhalable products and those 
      easily confused with non-cannabis products.
FAU - Orenstein, Daniel G
AU  - Orenstein DG
AD  - a Postdoctoral Fellow, Center for Tobacco Control Research and Education and 
      Philip R. Lee Institute for Health Policy Studies, University of California San 
      Francisco , San Francisco , CA , UA.
FAU - Glantz, Stanton A
AU  - Glantz SA
AUID- ORCID: 0000-0003-4620-6672
AD  - b Professor of Medicine, Truth Initiative Distingished Professor of Tobacco 
      Control, Center for Tobacco Control Research and Education, Philip R. Lee 
      Institute for Health Policy Studies, and Department of Medicine , University of 
      California San Francisco , San Francisco , CA , USA.
LA  - eng
GR  - R01 DA043950/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180213
PL  - United States
TA  - J Psychoactive Drugs
JT  - Journal of psychoactive drugs
JID - 8113536
RN  - 0 (Medical Marijuana)
SB  - IM
MH  - Adult
MH  - California
MH  - Drug Labeling/legislation & jurisprudence
MH  - Drug Packaging/legislation & jurisprudence
MH  - Humans
MH  - Industry/*legislation & jurisprudence
MH  - *Medical Marijuana
MH  - Product Labeling/legislation & jurisprudence
MH  - Product Packaging/legislation & jurisprudence
MH  - *Public Health
MH  - Tobacco Industry/*legislation & jurisprudence
PMC - PMC5878137
MID - NIHMS938636
OTO - NOTNLM
OT  - Cannabis
OT  - marijuana concentrates
OT  - marijuana edibles
OT  - marijuana extracts
OT  - marijuana labeling
OT  - marijuana legalization
EDAT- 2018/02/14 06:00
MHDA- 2019/10/12 06:00
PMCR- 2019/02/13
CRDT- 2018/02/14 06:00
PHST- 2018/02/14 06:00 [pubmed]
PHST- 2019/10/12 06:00 [medline]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2019/02/13 00:00 [pmc-release]
AID - 10.1080/02791072.2017.1422816 [doi]
PST - ppublish
SO  - J Psychoactive Drugs. 2018 Jan-Mar;50(1):19-32. doi: 
      10.1080/02791072.2017.1422816. Epub 2018 Feb 13.